HANSOH PHARMA’S AMEILE (ALMONERTINIB) RECEIVES MARKETING AUTHORIZATION IN CHINA FOR SECOND-LINE TREATMENT FOR PATIENTS WITH EGFR T790M-MUTATION NON-SMALL CELL LUNG CANCER
Shanghai, China – March 19, 2020 – Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, announ...
2020.03.19
